Company Description
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases.
Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.
In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.
The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors.
Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 48 |
| CEO | Timothy Lu |
Contact Details
Address: 2 Corporate Drive, First Floor South San Francisco, California 94080 United States | |
| Phone | 650 239 2030 |
| Website | sentibio.com |
Stock Details
| Ticker Symbol | SNTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001854270 |
| CUSIP Number | 81726A100 |
| ISIN Number | US81726A1007 |
| Employer ID | 86-2437900 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Timothy Lu | Chief Executive Officer |
| Yvonne Li | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | D | Notice of Exempt Offering of Securities |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 4, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 3, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 144 | Filing |
| Dec 2, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 25, 2024 | 8-K | Current Report |